Letrozole 2.5mg

Letrozole 2.5 mg

Brand: Magnus Pharmaceuticals
Content: 50 tablets | 2.5 mg per tablet
Price: €39
Manufactured in: Europe

🧪 Product Overview

Letrozole 2.5 mg is a third-generation, non-steroidal aromatase inhibitor (AI) that irreversibly binds the CYP19 enzyme to suppress estrogen biosynthesis. Designed for advanced hormone modulation studies, it supports research into testosterone enhancement, post-cycle therapy (PCT), fertility pathways, and estrogen-receptor positive (ER+) tumor models.

A single 2.5 mg oral dose reduces serum estradiol (E₂) by 60–80% within 24 hours and maintains suppression for ≥48 hours, supported by a 42–48 hour mean half-life. In male models, letrozole increases LH, FSH, and endogenous testosterone while improving sperm count—without impacting adrenal androgens. Exposure is prohibited in all WADA-sanctioned settings.

✅ Key Research Highlights

Potent estrogen suppression:
≥80% reduction in serum estradiol (E₂) achieved within 24 h after 2.5 mg dosing [NCBI]

Endogenous testosterone boost:
Studies in male infertility show ↑ LH, FSH, T, and sperm quality after 8–16 weeks [ScienceDirect, PMC]

Pharmacokinetics:
Oral bioavailability ~100%, t½ ≈ 42–48 h, steady-state in 2–6 weeks [DrugBank, PMC]

Common side effects:
Hot-flushes, joint discomfort, fatigue, and menopausal-like symptoms [NHS, Breast Cancer Now]

Long-term risks:
Reductions in bone-mineral density and lipid imbalances documented in chronic protocols [PMC]

🧬 Suggested Laboratory Applications

Aromatase inhibition and estrogen suppression modeling

Testosterone recovery and hormonal modulation

Fertility enhancement trials in male hypogonadism

PCT protocols in anabolic research models

ER+ breast cancer resistance pathways (e.g. tamoxifen-resistant models)

📊 Technical Specifications

Field	Data
Chemical Name	Letrozole
Chemical Formula	C17H11N5
Synonyms	Femara, CGP 57148, 4,4′-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile
Molecular Weight	285.3 g/mol
CAS Number	112809-51-5
Half-life	42–48 hours
Detection Window	≥2 days (varies by protocol)
Documented Benefits	↓ estrogen ≥80%, ↑ LH/FSH, ↑ T, fertility support, anti-ER+ tumor adjunct
Main Risks	↓ BMD, joint pain, lipid alterations, fatigue, menopausal symptoms
Total Active Compound	125 mg per carton (2.5 mg × 50 tablets)
Shelf-life	36 months (manufacturer specification)

❄️ PubChem-Supported Research Insights

Irreversibly inhibits aromatase enzyme (CYP19)

Maintains ≥80% estradiol suppression for 48+ hours

Improves testosterone-to-estradiol ratio without adrenal disruption

Increases LH and FSH in male fertility research

Used as an adjunct in tamoxifen-resistant ER+ tumor protocols

⚠️ Documented Research Side Effects

Hot flashes and joint discomfort common

Potential for bone-density loss with chronic use

Altered lipid profiles: ↑ LDL / ↓ HDL

Fatigue and hormonal mood shifts

High doping detectability under WADA S4 classification

🧯 Handling & Compliance

For Research Use Only — Not for human or veterinary use
Store at 15–25 °C, protect from light and moisture
Purchase confirms qualified researcher status
Listed on WADA Prohibited List S4 — any exposure may yield a positive doping result